Condition: Breast Cancer Metastatic · Breast Cancer Brain Metastases · Sponsor: Fudan University
In phase Ib, our study is aimed to evaluate the safety and tolerance of SHR-A1811 combined with pyrotinib in breast cancer with brain metastasis, and confirm the recommended phase 2 dose combined with preliminary results of efficacy. In phase II, our study is aimed to evaluate the efficacy and safety of SHR-A1811 combined with pyrotinib and bevacizumab at RP2D in breast cancer with brain metastasis.
This description comes directly from the study's public registry record.
Hongxia Wang, Chief physician · +8621-38196379 · whx365@126.com
Ting Li, Associate chief physician · +86-18121299346 · cinderellaliting@126.com
Always discuss trial participation with your own doctor first.
| Fudan Cancer Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06718933